Crossmark

Author response to: OSIN-D-24–01586, “Revisiting the safety of romosozumab in Japan: the need for clear contraindications for patients with cardiovascular risk”

Crossref DOI link: https://doi.org/10.1007/s00198-024-07348-2

Published Online: 2025-01-08

Published Print: 2025-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Masuda, Soichiro

Fukasawa, Toshiki

Matsuda, Shuichi

Yoshida, Satomi

Kawakami, Koji https://orcid.org/0000-0002-7477-4071
License Information

Text and Data Mining valid from 2025-01-08

Version of Record valid from 2025-01-08
More Information

Article History

Received: 8 December 2024

Accepted: 10 December 2024

First Online: 8 January 2025

Declarations

:

: Toshiki Fukasawa receives research funding from AstraZeneca K.K.; consulting fees from Real World Data Co., Ltd. and JMDC Inc.; honoraria from the Research Institute of Healthcare Data Science (RIHDS); and was previously employed by the Department of Digital Health and Epidemiology at Kyoto University, which was supported by Eisai Co., Ltd. and Kyowa Kirin Co., Ltd. Koji Kawakami receives research funding from AstraZeneca K.K., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., OMRON Corporation, and Toppan Inc.; consulting fees from Advanced Medical Care Inc., JMDC Inc., LEBER Inc., Santen Pharmaceutical Co., Ltd., Shin Nippon Biomedical Laboratories Ltd., and Ubicom Holdings Inc.; executive compensation from Cancer Intelligence Care Systems, Inc.; and honoraria from Pharma Business Academy Co., Ltd., Shionogi & Co., Ltd., and Taisho Pharmaceutical Co., Ltd.; and held stock in Real World Data Co., Ltd.

Document is current

Any future updates will be listed below